Pharmacological Properties of BN82451: a Novel Multitargeting Neuroprotective Agent

Overview

Journal CNS Drug Rev

Specialties Neurology
Pharmacology

Date 2007 Sep 27

PMID 17894648

Citations 11

Authors

Pierre Etienne Chabrier

Michel Auguet

Affiliations

Soon will be listed here.

Abstract

BN82451 belongs to a new family of small molecules designated as multitargeting or hybrid molecules. BN82451 is orally active, has good central nervous system penetration, and elicits potent neuronal protection and antiinflammatory properties. Neuronal protection is due to Na+ channel blockade, antioxidant properties, and mitochondria-protecting activity, whereas inhibition of cyclooxygenases is mostly responsible for its antiinflammatory activity. BN82451 has been shown to exert a potent neuroprotective effect in various in vitro and in vivo animal models. BN82451 was found to exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis. Collectively, its pharmacological properties designate BN82451 as a promising neuroprotective agent.

Citing Articles

Navigating the dichotomy of reactive oxygen, nitrogen, and sulfur species: detection strategies and therapeutic interventions.

Baruah P, Padhi D, Moorthy H, Ramesh M, Govindaraju T RSC Chem Biol. 2025; 6(3):338-357.

PMID: 39877134 PMC: 11770382. DOI: 10.1039/d5cb00006h.

Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders.

Singh K, Gupta J, Sethi P, Mathew S, Bhatt A, Sharma M Curr Top Med Chem. 2024; 24(22):1940-1959.

PMID: 39108007 DOI: 10.2174/0115680266305736240725052825.

Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing.

Makeeva V, Dyrkheeva N, Lavrik O, Zakian S, Malakhova A Int J Mol Sci. 2023; 24(23).

PMID: 38069121 PMC: 10706709. DOI: 10.3390/ijms242316798.

Neurodegenerative Diseases: New Hopes and Perspectives.

Bhat M, Dhaneshwar S Curr Mol Med. 2023; 24(8):1004-1032.

PMID: 37691199 DOI: 10.2174/1566524023666230907093451.

Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington's Disease.

DEgidio F, Castelli V, Cimini A, dAngelo M Antioxidants (Basel). 2023; 12(3).

PMID: 36978821 PMC: 10045781. DOI: 10.3390/antiox12030571.

References

Baltuch G . Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci. 1999; 22:219-40. DOI: 10.1146/annurev.neuro.22.1.219. View

Friberg H, Connern C, Halestrap A, Wieloch T . Differences in the activation of the mitochondrial permeability transition among brain regions in the rat correlate with selective vulnerability. J Neurochem. 1999; 72(6):2488-97. DOI: 10.1046/j.1471-4159.1999.0722488.x. View

Floyd R . Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med. 1999; 26(9-10):1346-55. DOI: 10.1016/s0891-5849(98)00293-7. View

Chabrier P, Auguet M, Spinnewyn B, Auvin S, Cornet S, Marin J . BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc Natl Acad Sci U S A. 1999; 96(19):10824-9. PMC: 17967. DOI: 10.1073/pnas.96.19.10824. View

Kristian T, Gertsch J, Bates T, Siesjo B . Characteristics of the calcium-triggered mitochondrial permeability transition in nonsynaptic brain mitochondria: effect of cyclosporin A and ubiquinone O. J Neurochem. 2000; 74(5):1999-2009. DOI: 10.1046/j.1471-4159.2000.0741999.x. View

Marin J, Auguet M, Chabrier P . In vitro antioxidant neuroprotective activity of BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation. J Neurochem. 2000; 74(5):2079-86. DOI: 10.1046/j.1471-4159.2000.0742079.x. View

Barclay L, Vinqvist M . Do spin traps also act as classical chain-breaking antioxidants? A quantitative kinetic study of phenyl tert-butylnitrone (PBN) in solution and in liposomes. Free Radic Biol Med. 2000; 28(7):1079-90. DOI: 10.1016/s0891-5849(00)00197-0. View

Ikegaya H, Iwase H, Hatanaka K, Sakurada K, Yoshida K, TAKATORI T . Diagnosis of cyanide intoxication by measurement of cytochrome c oxidase activity. Toxicol Lett. 2001; 119(2):117-23. DOI: 10.1016/s0378-4274(00)00297-6. View

Doble A, Kennel P . Animal models of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1(5):301-12. DOI: 10.1080/146608200300079545. View

10.

Desnuelle C, Dib M, Garrel C, Favier A . A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(1):9-18. DOI: 10.1080/146608201300079364. View

11.

Andreassen O, Ferrante R, Dedeoglu A, Beal M . Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport. 2001; 12(15):3371-3. DOI: 10.1097/00001756-200110290-00044. View

12.

Krieger C, Duchen M . Mitochondria, Ca2+ and neurodegenerative disease. Eur J Pharmacol. 2002; 447(2-3):177-88. DOI: 10.1016/s0014-2999(02)01842-3. View

13.

Kristian T, Weatherby T, Bates T, Fiskum G . Heterogeneity of the calcium-induced permeability transition in isolated non-synaptic brain mitochondria. J Neurochem. 2002; 83(6):1297-308. DOI: 10.1046/j.1471-4159.2002.01238.x. View

14.

Zhang W, Narayanan M, Friedlander R . Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003; 53(2):267-70. DOI: 10.1002/ana.10476. View

15.

Nagano S, Fujii Y, Yamamoto T, Taniyama M, Fukada K, Yanagihara T . The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp Neurol. 2003; 179(2):176-80. DOI: 10.1016/s0014-4886(02)00014-6. View

16.

Kriz J, Gowing G, Julien J . Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol. 2003; 53(4):429-36. DOI: 10.1002/ana.10500. View

17.

Klivenyi P, Ferrante R, Gardian G, Browne S, Chabrier P, Beal M . Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem. 2003; 86(1):267-72. DOI: 10.1046/j.1471-4159.2003.t01-1-01868.x. View

18.

Snow R, Turnbull J, da Silva S, Jiang F, Tarnopolsky M . Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience. 2003; 119(3):661-7. DOI: 10.1016/s0306-4522(03)00212-4. View

19.

WINTER C, RISLEY E, NUSS G . Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962; 111:544-7. DOI: 10.3181/00379727-111-27849. View

20.

Pearce L, Bominaar E, Hill B, Peterson J . Reversal of cyanide inhibition of cytochrome c oxidase by the auxiliary substrate nitric oxide: an endogenous antidote to cyanide poisoning?. J Biol Chem. 2003; 278(52):52139-45. DOI: 10.1074/jbc.M310359200. View